FIXX News and Press, Homology Medicines Inc.

2024-03-25 09:02:02 ET Homology Medicines Inc (FIXX) announced stock split at a ratio of 1-for-18 on 2024-03-25 ... Full story available on KlickAnalytics.com

BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstandi...

2024-01-03 16:15:20 ET More on Homology Medicines Homology Medicines slumps after merger deal with Q32 Bio Seeking Alpha’s Quant Rating on Homology Medicines Historical earnings data for Homology Medicines Financial information for Homology Medicines ...

Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“ Nasdaq Notif...

2023-11-16 12:26:59 ET Gene therapy company Homology Medicines ( NASDAQ: FIXX ) lost ~47% on Thursday after Q32 Bio, a privately held biotech based in Waltham, Massachusetts, agreed to merge with it in an all-stock transaction. The combined entity will focus on Q32 Bio's exp...

Q32 Bio and Homology Medicines Announce Merger Agreement PR Newswire --The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) an...

2023-11-14 17:58:12 ET More on Homology Medicines Seeking Alpha’s Quant Rating on Homology Medicines Historical earnings data for Homology Medicines Financial information for Homology Medicines For further details see: Homology Medicines GAAP EPS o...

- Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 - BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financia...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Homology Medicines Inc. (FIXX) is expected to report $-0.42 for Q3 2023